Article Figures & Data
Figures
- Figure 1.
Treatment response (A) and progression-free survival (PFS) with panitumumab (B) in metastatic colorectal cancer patients after progression on cetuximab. PR, Partial response; CR, complete response; SD, stable disease; PD, progressive disease.
- Figure 2.
Relationship of cetuximab and consequent panitumumab therapeutic response and progression-free survival (PFS). Response to panitumumab in patients stratified according to their response to cetuximab (A). PFS with panitumumab treatment according to cetuximab treatment response (B). PFS with panitumumab according to median PFS on cetuximab treatment (C). PR, Partial response; CR, complete response; SD, stable disease; PD, progressive disease.
- Figure 3.
MiR-31-5p as predictive biomarker to anti-epidermal growth factor receptor (EGFR) therapy. Progression-free survival (PFS) from cetuximab treatment initiation according to miR-31-5p expression levels (A). PFS from panitumumab treatment initiation according to miR-31-5p expression level (B).
